Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldstein

Showing results (161-170 of 518) with videos related to

Pageof 52
Sort By:
The Oncologist|April 12, 2011
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilitySusanna B Park, Cindy S Y Lin, Arun V Krishnan, et al.
Oncotarget|February 1, 2020
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomasXiaochun Wang, Reichelle X Yeo, Philip J Hogg, et al.
ANZ Journal of Surgery|November 20, 2004
Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experienceBrett G M Hughes, Desmond Yip, Michael Chao, et al.
Oncology|December 18, 2009
Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicitySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
The Australian Journal of Rural Health|November 26, 2009
Mapping oncology services in regional and rural AustraliaCraig Underhill, Rebecca Bartel, David Goldstein, et al.
The Journal of Infectious Diseases|July 12, 2011
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infectionJohn Scott, Sarah Holte, Thomas Urban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?Susanna B Park, David Goldstein, Cindy S-Y Lin, et al.
Plos One|April 16, 2011
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicitySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
Pancreas|November 6, 2019
Evaluation of Phase II Trial Design in Advanced Pancreatic CancerMonica Tang, Julia Chen, David Goldstein, et al.
Cornea|September 26, 2022
Reproducibility and Reliability of Subbasal Corneal Nerve Parameters of the Inferior Whorl in the Neurotoxic and Healthy CorneaJeremy Chung Bo Chiang, Vincent Khou, Azadeh Tavakoli, et al.
Pageof 52

Showing results (161-170 of 518) with videos related to

Sort By:
Pageof 52
The Oncologist|April 12, 2011
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilitySusanna B Park, Cindy S Y Lin, Arun V Krishnan, et al.
Oncotarget|February 1, 2020
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomasXiaochun Wang, Reichelle X Yeo, Philip J Hogg, et al.
ANZ Journal of Surgery|November 20, 2004
Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experienceBrett G M Hughes, Desmond Yip, Michael Chao, et al.
Oncology|December 18, 2009
Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicitySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
The Australian Journal of Rural Health|November 26, 2009
Mapping oncology services in regional and rural AustraliaCraig Underhill, Rebecca Bartel, David Goldstein, et al.
The Journal of Infectious Diseases|July 12, 2011
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infectionJohn Scott, Sarah Holte, Thomas Urban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?Susanna B Park, David Goldstein, Cindy S-Y Lin, et al.
Plos One|April 16, 2011
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicitySusanna B Park, Cindy S-Y Lin, Arun V Krishnan, et al.
Pancreas|November 6, 2019
Evaluation of Phase II Trial Design in Advanced Pancreatic CancerMonica Tang, Julia Chen, David Goldstein, et al.
Cornea|September 26, 2022
Reproducibility and Reliability of Subbasal Corneal Nerve Parameters of the Inferior Whorl in the Neurotoxic and Healthy CorneaJeremy Chung Bo Chiang, Vincent Khou, Azadeh Tavakoli, et al.
Pageof 52